In order to identify immune evasion mechanisms operative in melanoma, we used a transplantable tumor cell line established from a Braf+/LSL-V600E;Tyr::CreERT2+/o;p16INK4a−/− mouse (Dhomen et al., 2009) (henceforth, BrafV600E cells). This evidence concerns the gene CDKN2A and melanoma.